vs
Apellis Pharmaceuticals, Inc.（APLS）与California Resources Corp（CRC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是California Resources Corp的1.7倍（$199.9M vs $119.0M），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-32.0M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -46.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
加州资源集团是一家美国能源企业，主要在加州开展油气勘探业务。公司注册地为特拉华州，总部位于加州长滩，所持有的加州矿产地块面积是该州私有主体中的最高水平。
APLS vs CRC — 直观对比
营收规模更大
APLS
是对方的1.7倍
$119.0M
自由现金流更多
APLS
多$17.7M
$-32.0M
两年增速更快
APLS
近两年复合增速
-46.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $119.0M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -597.5% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-8.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCRC
| Q1 26 | — | $119.0M | ||
| Q4 25 | $199.9M | $679.0M | ||
| Q3 25 | $458.6M | $715.0M | ||
| Q2 25 | $178.5M | $702.0M | ||
| Q1 25 | $166.8M | $814.0M | ||
| Q4 24 | $212.5M | $826.0M | ||
| Q3 24 | $196.8M | $870.0M | ||
| Q2 24 | $199.7M | $412.0M |
净利润APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | $-59.0M | $12.0M | ||
| Q3 25 | $215.7M | $64.0M | ||
| Q2 25 | $-42.2M | $172.0M | ||
| Q1 25 | $-92.2M | $115.0M | ||
| Q4 24 | $-36.4M | $33.0M | ||
| Q3 24 | $-57.4M | $345.0M | ||
| Q2 24 | $-37.7M | $8.0M |
营业利润率APLSCRC
| Q1 26 | — | -597.5% | ||
| Q4 25 | -25.6% | 6.9% | ||
| Q3 25 | 48.7% | 13.7% | ||
| Q2 25 | -18.6% | 38.0% | ||
| Q1 25 | -50.0% | 22.9% | ||
| Q4 24 | -12.3% | 8.2% | ||
| Q3 24 | -24.0% | 59.5% | ||
| Q2 24 | -14.7% | 9.2% |
净利率APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | -29.5% | 1.8% | ||
| Q3 25 | 47.0% | 9.0% | ||
| Q2 25 | -23.6% | 24.5% | ||
| Q1 25 | -55.3% | 14.1% | ||
| Q4 24 | -17.1% | 4.0% | ||
| Q3 24 | -29.2% | 39.7% | ||
| Q2 24 | -18.9% | 1.9% |
每股收益（稀释后）APLSCRC
| Q1 26 | — | $-8.02 | ||
| Q4 25 | $-0.40 | $0.21 | ||
| Q3 25 | $1.67 | $0.76 | ||
| Q2 25 | $-0.33 | $1.92 | ||
| Q1 25 | $-0.74 | $1.26 | ||
| Q4 24 | $-0.30 | $0.87 | ||
| Q3 24 | $-0.46 | $3.78 | ||
| Q2 24 | $-0.30 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.9B |
| 总资产 | $1.1B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $132.0M | ||
| Q3 25 | $479.2M | $196.0M | ||
| Q2 25 | $370.0M | $72.0M | ||
| Q1 25 | $358.4M | $214.0M | ||
| Q4 24 | $411.3M | $372.0M | ||
| Q3 24 | $396.9M | $241.0M | ||
| Q2 24 | $360.1M | $1.0B |
总债务APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.2B |
股东权益APLSCRC
| Q1 26 | — | $2.9B | ||
| Q4 25 | $370.1M | $3.7B | ||
| Q3 25 | $401.2M | $3.4B | ||
| Q2 25 | $156.3M | $3.4B | ||
| Q1 25 | $164.2M | $3.5B | ||
| Q4 24 | $228.5M | $3.5B | ||
| Q3 24 | $237.1M | $3.5B | ||
| Q2 24 | $264.3M | $2.1B |
总资产APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $7.4B | ||
| Q3 25 | $1.1B | $6.8B | ||
| Q2 25 | $821.4M | $6.7B | ||
| Q1 25 | $807.3M | $6.8B | ||
| Q4 24 | $885.1M | $7.1B | ||
| Q3 24 | $901.9M | $7.1B | ||
| Q2 24 | $904.5M | $4.5B |
负债/权益比APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.57× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $99.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-32.0M |
| 自由现金流率自由现金流/营收 | -7.1% | -26.9% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $380.0M |
8季度趋势，按日历期对齐
经营现金流APLSCRC
| Q1 26 | — | $99.0M | ||
| Q4 25 | $-14.2M | $235.0M | ||
| Q3 25 | $108.5M | $279.0M | ||
| Q2 25 | $4.4M | $165.0M | ||
| Q1 25 | $-53.4M | $186.0M | ||
| Q4 24 | $19.4M | $206.0M | ||
| Q3 24 | $34.1M | $220.0M | ||
| Q2 24 | $-8.3M | $97.0M |
自由现金流APLSCRC
| Q1 26 | — | $-32.0M | ||
| Q4 25 | $-14.3M | $115.0M | ||
| Q3 25 | $108.3M | $188.0M | ||
| Q2 25 | $4.4M | $109.0M | ||
| Q1 25 | $-53.4M | $131.0M | ||
| Q4 24 | $19.3M | $118.0M | ||
| Q3 24 | — | $141.0M | ||
| Q2 24 | $-8.4M | $63.0M |
自由现金流率APLSCRC
| Q1 26 | — | -26.9% | ||
| Q4 25 | -7.1% | 16.9% | ||
| Q3 25 | 23.6% | 26.3% | ||
| Q2 25 | 2.5% | 15.5% | ||
| Q1 25 | -32.0% | 16.1% | ||
| Q4 24 | 9.1% | 14.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | -4.2% | 15.3% |
资本支出强度APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 17.7% | ||
| Q3 25 | 0.0% | 12.7% | ||
| Q2 25 | 0.0% | 8.0% | ||
| Q1 25 | 0.0% | 6.8% | ||
| Q4 24 | 0.0% | 10.7% | ||
| Q3 24 | 0.0% | 9.1% | ||
| Q2 24 | 0.0% | 8.3% |
现金转化率APLSCRC
| Q1 26 | — | — | ||
| Q4 25 | — | 19.58× | ||
| Q3 25 | 0.50× | 4.36× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 1.62× | ||
| Q4 24 | — | 6.24× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 12.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CRC
暂无分部数据
